A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

Pfizer

Status and phase: Completed; Phase 1

Conditions: Schizophrenia

Treatments: Drug: PF-3463275; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00567203

A9131004

Details and patient eligibility

About

The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with chronic symptoms of schizophrenia.

Enrollment: 36 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of schizophrenia
• In stable treatment with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone for at least 2 months
• Stable symptoms of schizophrenia for at least 3 months.

Exclusion criteria

• Subjects with a psychiatric disorder other than schizophrenia
• Substance dependence or abuse
• Women who have child bearing potential.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

36 participants in 3 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: PF-3463275

Drug: PF-3463275

2

Experimental group

Treatment:

Drug: PF-3463275

Drug: PF-3463275

3

Placebo Comparator group

Treatment:

Drug: Placebo